Jackson Square Partners’s 10x Genomics TXG Stock Holding History

Jackson Square Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-211,050	Closed	-$9.55M	–	90
2022 Q2	$9.55M	Sell	211,050 -369,389	-64%	-$19.2M	0.22%	53
2022 Q1	$44.2M	Buy	580,439 +188,414	+48%	+$16.5M	0.44%	68
2021 Q4	$58.4M	Sell	392,025 -426,801	-52%	-$65.4M	0.49%	62
2021 Q3	$119M	Sell	818,826 -98,204	-11%	-$16.9M	0.76%	50
2021 Q2	$180M	Buy	917,030 +75,273	+9%	+$13.6M	1.03%	41
2021 Q1	$152M	Buy	+841,757	New	+$145M	0.87%	51

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jackson Square Partners's TXG Position: Q3 2022 in Review

Jackson Square Partners sold out of 10x Genomics (TXG) in Q3 2022, closing a stake of 211,050 shares — an estimated $9.55M sold.

Jackson Square Partners first reported a position in TXG in Q1 2021 and held it in 6 quarters. The position peaked at $180M in Q2 2021. 233 funds tracked by Wall St. Rank hold TXG as of Q3 2022.

Jackson Square Partners reported no remaining 10x Genomics position as of Q3 2022 after selling out during the quarter.
Jackson Square Partners sold 211,050 10x Genomics shares in Q3 2022, an estimated $9.55M.
Jackson Square Partners first reported a position in 10x Genomics in Q1 2021 and held it in 6 quarters.
Jackson Square Partners's 10x Genomics position peaked at $180M in Q2 2021.
233 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2022.

Based on Jackson Square Partners's 13F filing for Q3 2022, filed 14 Nov 2022.